OB318

OB318 is an oral small molecule drug developed by Oneness Biotech for the treatment of advanced solid malignancies, with a primary focus on hepatocellular carcinoma (HCC), the most common type of liver cancer. It is derived as an extract from Antrodia mycelium and classified as both a traditional Chinese medicine and a novel anti-cancer agent. The drug acts through multiple mechanisms, including inhibition of cancer cell growth, angiogenesis (formation of new blood vessels that supply tumors), and metastasis (spread of cancer cells). Its molecular targets include phosphatidylinositol 3 kinase alpha (PI3Kα), serine/threonine-protein kinase AKT-1, and serine/threonine-protein kinase mTOR—key components in pathways regulating cell proliferation and survival. Clinical development has reached phase 1/2 trials for advanced solid tumors and hepatocellular carcinoma[1][2][3][4][5][7].